Search the Newsreel

H.C. Wainwright raises Alto Neuroscience price target to $55

H.C. Wainwright has increased its price target for Alto Neuroscience (NYSE:ANRO) to $55 from $50, maintaining a Buy rating. This adjustment follows Alto's announcement of its Q2 2026 results and the naming of its ALTO-207 development plan as the PACE program, which includes three …

Gilead Sciences Inc (GILD) Stock Up 3.2% but GF Value Says Overvalued

Gilead Sciences Inc (GILD) shares increased by 3.2% to $143.44, but GuruFocus's GF Value indicates the stock is 34.9% overvalued, with an estimated intrinsic value of $106.32. The company's GF Score is 74/100, highlighting strong profitability but weak momentum and insider selling of $77.5 …

USANA (USNA) Q2 2026 Earnings Call Transcript

Ciena (NYSE: CIEN) exec sells 2,500 shares under trading plan

David M. Rothenstein, SVP and Chief Strategy Officer of Ciena (NYSE: CIEN), sold 2,500 shares of common stock on August 14, 2026, at $438.10 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on October 10, 2025. Following the sale, …

Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan

Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, …

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Sabrina Martucci Johnson, CEO of Daré Bioscience, has been recognized on Forbes' 2026 “50 Over 50: Innovation” list for her significant impact in women's health. The company, founded in 2015, is evolving from a clinical-stage biotechnology firm to a multi-product women's health company with …

SELLAS (SLS) Earnings Recap: EPS Misses Its Estimate in the Reported Period; Trading Response: Shares Move Higher 0.77% for the Current Session - Return On Assets

Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates

BioHarvest (BHST) Earnings Recap: The Available Earnings Metric Delivers a Miss in the Reported Period; The Stock Loses 1.15% in the Available Record - Earnings Manipulation Risk

Ciena (NYSE: CIEN) exec sale leaves 38,407-share stake

Ciena's Senior Vice President, Gage Brodie, sold 1,200 shares of common stock at $439.24 per share on August 17, 2026, as per a Rule 10b5-1 trading plan. Following this transaction, Brodie retains a beneficial ownership of 38,407 shares, which includes unvested Restricted Stock Units …

Castle Biosciences (CSTL) CFO sells 24,908 company shares

Castle Biosciences (CSTL) Chief Financial Officer, Frank Stokes, sold 24,908 shares of common stock on August 14, 2026, at a weighted-average price of $29.77 per share. The transaction, executed in multiple trades between $29.71 and $29.97, resulted in Stokes directly holding 35,177 shares after …

Edwards Lifesciences stock holds steady as analysts see upside

Edwards Lifesciences (EW) stock is trading in the low-$90s with a moderate buy consensus and an average analyst price target of $100.27, suggesting a high-single-digit upside. Institutional investors are increasing their exposure to the company, and its transcatheter heart valve systems remain a key …

NovaBridge (NBP) Latest Results Brief: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Earnings Trading: The Stock Ends Down 2.07% in the Current Update - Operating Income Trends

Cogent (COGT) Q1 2026 Earnings: EPS Misses Its Estimate in the Latest Session; Investor Response: The Share Price Sheds 1.35% in Latest Trading - CEO Earnings Statement

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18

Cellectar Biosciences, Inc. (CLRB) discussed the scientific rationale and potential of its Phospholipid Ether Platform in targeted cancer therapy. This information was presented in a slideshow in conjunction with an event. The article highlights the company's focus on developing cancer therapies using this platform.

Is Gilead's Expanding HIV Portfolio a Growth Catalyst?

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention. Earlier this month, the company reported better-than-expected second-quarter results, driven by strong HIV breast cancer drug Trodelvy and liver disease drug Livdelzi …

Gilead Sciences Inc Stock (GILD) Moved Up by 3.14% on Aug 18: Drivers Behind the Movement

Gilead Sciences Inc (GILD) stock rose 3.14% on August 18, driven by a federal court injunction protecting its HIV medications, robust base-business revenue growth, and strategic oncology investments. Positive market sentiment was also fueled by bullish institutional options activity and strong fundamental performance, despite …

Vita Life Sciences (ASX:VLS) Shares Reflect A Stronger Margin Story

SELLAS (SLS) Q1 2026 Results: The Bottom-Line Figure Trails Its Comparison in Latest Trading; Reaction Snapshot: Shares Move Higher 1.08% - Revenue Warning Signal

Achieve (ACHV) Earnings Check: Reported EPS Tops Expectations in the Latest Session; Closing Response

Boston Scientific Corp. stock underperforms Tuesday when compared to competitors

Boston Scientific Corp. (BSX) shares fell by 1.87% on Tuesday, closing at $50.47, underperforming its competitors and the broader market. This decline occurred during a generally down trading session, with the S&P 500 Index falling 0.69% and the Dow Jones Industrial Average dropping 0.22%. …

Pulse (PLSE) Earnings Review: EPS Exceeds Its Estimate in the Current Update; Reaction Snapshot

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Gilead Sciences Inc. (GILD) stock saw a daily gain of 3.25% on Tuesday, closing at $143.44. Despite this increase, the stock underperformed compared to broader market indices, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) also experiencing declines. This marked …

Boston Scientific stock holds in the low $51 range as Q2 2026 margins and EPS beat guidance

Boston Scientific's stock is trading in the low $51 range despite the company reporting stronger-than-expected Q2 2026 results, including increased margins and adjusted EPS that surpassed guidance. The medical device group saw its stock decline by 46% from the start of 2026, leading to …

Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current Update - Debt Analysis Report

Eurofins Scientific SE: Weekly Report on Share Repurchases from 10th August to 14th August 2026

LUXEMBOURG, August 18, 2026--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC …

Anavex (AVXL) Q2 2026 Results: EPS Prints Above Forecast in Latest Trading; Reaction Snapshot: Shares Finish 3.27% Down - Revenue Warning Signal

Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current Update - Pre-Earnings Setup

Anixa (ANIX) Latest Results Brief: EPS Prints Above Forecast at the Close; Post-Earnings Trading: Shares Finish 3.30% Lower in the Latest Reading - EBITDA Analysis

Burcon NutraScience Stock Falls 7.50%: Is TSX:BU Facing a Commercialization Reality Check?

Twist Bioscience (NASDAQ: TWST) insider plans multimillion-dollar stock sale

An officer at Twist Bioscience (TWST), Patrick Finn, has filed a Rule 144 notice to sell up to 78,355 shares of common stock through Fidelity Brokerage Services LLC, valued at approximately $9.5 million. These shares were primarily acquired through restricted stock vesting and a …

Boston Scientific Stimulator Lawsuit Alleges Spine Implant Caused Nerve Damage, Shocks

A Kentucky man has filed a product liability lawsuit against Boston Scientific, alleging that its spinal cord stimulator caused unexpected electric shocks and permanent nerve damage, despite being marketed for chronic pain relief. The lawsuit claims Boston Scientific knew about the device's "unacceptably high …

Why Satellos Bioscience Inc. stock is gaining today

Castle Biosciences (CSTL) Edges Lower to $29.66: Diagnostic Stock Holds Key Support Zone - Profitability Factor

TD Cowen Lowers Ciena (NYSE:CIEN) Price Target to $575.00

TD Cowen has reduced its price target for Ciena (NYSE:CIEN) to $575.00 from $675.00, while maintaining a "buy" rating, indicating a potential 40% upside. This adjustment comes despite Ciena reporting strong quarterly earnings and revenue that surpassed analyst expectations, with revenue increasing 39.5% year-over-year. …

Why COSCIENS Biopharma Inc. stock is plummeting today